Abstract: Background: C-reactive protein is an inflammatory biomarker and its level increases in the serum of psoriatic patients. Its level is also associated with Psoriasis Area and Severity Index score. oBjective: The aim of this study was to assess the decrement of serum C-reactive protein level with narrow-band ultraviolet B (NB-UVB) therapy. Methods: C-reactive protein serum levels in psoriasis patients were measured before and after treatment with NB-UVB and the data were analyzed in relation to the Psoriasis Area and Severity Index score improvement. results: Baseline C-reactive protein levels among psoriatic patients were higher than normal. These levels decreased significantly after treatment (P<0.001). At the beginning of the study, patients with higher levels of C-reactive protein also had more extensive and severe skin involvement. The highest decrease in C-reactive protein was observed in patients who responded better to the treatment and achieved a higher Psoriasis Area and Severity Index 75%. There was an association between baseline Psoriasis Area and Severity Index scores and C-reactive protein levels. conclusion: Patients with moderate to severe plaque-type psoriasis had active systemic inflammation, which was demonstrated by increased levels of C-reactive protein. Furthermore, skin disease severity was correlated with C-reactive protein levels. Phototherapy healed the psoriatic skin lesions and reduced inflammation, while decreasing C-reactive protein levels.
INTRODUCTION
Chronic plaque psoriasis is the most common type of psoriasis. It is estimated that the prevalence of psoriasis is 2%-5% worldwide. However, in Asia alone, the prevalence is 0.4%-0.7%. Psoriasis is determined by excessive proliferation and impaired evolution of keratinocytes. Due to its recurrent nature, psoriasis has a major impact on the patient's quality of life. 1 Phototherapy represents a mainstay treatment for psoriasis vulgaris. Psoriasis lesions can be healed by the narrow band ultraviolet B lights (NB-UVB) at a length of 311 nanometers, which has more impact than broadband ultraviolet over a short period; with only a 10% incidence of burning, compared with 28% for conventionally treated patients. 2 Psoriasis also has an inflammatory nature that is demonstrated by excessive secretion of dermal, systemic, pre-inflammatory cytokines such as IL-2, IL- 6,IL-12, IL8, IL-17, IL-19, IL-20, IL-22, IL-23, IL-24, IFN-γ and TNF-α. 3 Furthermore, liver stimulation and the production of acute phase reactants such as C-reactive protein (CRP), which is considered an inflammatory biomarker, are believed to stem from IL-6 secretion induced by TNF-α. 4 Patients who did not wish to complete the project were allowed to leave the study and subsequently excluded. Because participation was voluntary, refusal to participate involved no penalty or loss of benefits to which the subjects were otherwise entitled, and the subjects were permitted to discontinue participation at any time without penalty or loss of benefits to which the subjects were otherwise entitled. In sum, 30 patients started the study but 5 patients were excluded. Thus, the study continued with 25 cases of plaque type In this study, we assessed psoriasis severity based on PASI scores and the pre-and post-treatment scores. Finally, the difference between the initial PASI score and the final score was determined and PASI 75% was calculated based on Formula 1.
(Formula 1: how to calculate the lesion recovery rates: PASI % = (PASI 1 -PASI 2 ) / PASI 1 * 100). Phototherapy was conducted three times a week, using a wavelength of 311nm to treat the psoriatic lesions of patients with the first dose of 4% J/cm 2 . According to the predicted protocol from the skin department, the dose increased gradually, as shown in table 1.
Statistical analyses were performed based on initial and final CRP serum values, their changes pre-and post-treatment, and clinical criteria for determining PASI scores pre-and post-treatment.
At the end, the pair T test and Spearman correlation coefficient were used to compare the means, to express the relations between variables and frequency via the data description approach.
RESULTS
In total, out of 25 patients, there were 18 males (72%) and seven females (28%). They were treated by NB-UVB therapy. The ages of these patients ranged from 21 to 67 years, with a mean age of 41.08±14.60 years. All the results obtained are summarized in table 2. Our findings suggested that 16 patients achieved a 75% or more reduction in their PASI score from baseline. The maximum, minimum and mean pre-treatment CRP serum levels were 18.580 mg/l, 2.10 mg/l and 5.79±3.62 mg/l, respectively. Meanwhile, the maximum, minimum and mean pre-treatment PASI scores were 53.10, 9.10 and 22.20±11.51, respectively. However, the maximum, minimum and mean post-treatment CRP levels were 6.88mg/l, The variation values observed for pre-and post-treatment CRP serum levels are displayed in graph 1.
Pre-and post-treatment PASI scores, along with the relationship between post-treatment CRP serum levels and PASI 75%, are shown in graph 2 and graph 3, respectively.
DISCUSSION
CRP is an acute phase reactive protein, known as a systemic inflammatory biomarker. Serwin reported increased CRP concentrations in active psoriasis. 7 Uysal et al. identified CRP as a mark-582 Farshchian M, Ansar A, Sobhan M, Hoseinpoor V er for psoriasis severity. 5 Isha found that CRP levels increased by more than 20 times in psoriasis patients compared with the healthy individuals. After 12 weeks of treatment, it fell to nearly 50% of the initial value. 8 Similarly, we observed a significant decrease in post-treatment CRP serum levels due to NB-UVB phototherapy (P<0.001).
In a study conducted in 70 psoriasis patients, Biljan et al.
observed that inflammatory parameters such as CRP serum levels were significantly related to the clinical demonstrations of psoriasis (p<0.005). They also identified a relationship between disease severity and the increased levels of inflammatory reactions. 9 In a cross-sectional study conducted on 73 psoriasis patients, Coimbra et al. noted that CRP serum levels were related to PASI scores and that they could be reduced by using NB-UVB as a treatment. Consequently, it is suggested that CRP serum levels can be considered a useful marker for diagnosing psoriasis severity and monitoring disease activity or the disease's reaction to treatment. 10 In another study of 175 male psoriasis patients performed by Chodorowska, the clinical activity of psoriasis was calculated based on the PASI score, which reflected the increase in CRP serum levels during the acute phase (P<0.001). The relationship between CRP serum levels in 25 patients, pre-and post-treatment using NBUVB and PASI 75% graph 2: Comparison of PASI scores in 25 patients before and after treatment using NB-UVB can be used to evaluate the severity of psoriasis and its response to treatment. In addition, the inflammatory markers, together with the PASI score, may represent an inflammatory situation for psoriasis.
13

CONCLUSION
According to the data recorded in the literature and the current survey results, the augmented CRP serum levels were found in patients with moderate to severe plaque-type psoriasis, marking the systemic inflammatory feature of this disease. We gathered evidence that correlates psoriasis severity with CRP. The study suggested that CRP serum levels increase with psoriasis disease activity, which is
